• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Heron Therapeutics, Inc. - Common Stock (NQ:HRTX)

    0.5670 -0.2602 (-31.46%)
    Streaming Delayed Price Updated: 10:33 AM EDT, Jun 2, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 5,987,790
    Open 0.6750
    Bid (Size) 0.5669 (2,200)
    Ask (Size) 0.5670 (400)
    Prev. Close 0.8272
    Today's Range 0.5002 - 0.6900
    52wk Range 0.7362 - 2.300
    Shares Outstanding 140,759,276
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Tuesday's session: gap up and gap down stocks ↗
    Via Chartmill
    News headline image
    U.S. District Court Issues Decision Regarding CINVANTI® Patents
    After Reviewing the Ruling, Heron Believes It has Substantial Grounds for Obtaining Reversal in an Appeal 
    From Heron Therapeutics, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -55.0%
    -55.0%
    1 Month
    -53.5%
    -53.5%
    3 Month
    -52.8%
    -52.8%
    6 Month
    -50.7%
    -50.7%
    1 Year
    -70.6%
    -70.6%

    More News

    Read More
    Which stocks are moving after the closing bell on Monday? ↗
    Via Chartmill
    News headline image
    Heron (HRTX) Q1 2026 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings Supply Chain
    Heron Therapeutics Q1 Results Miss, but Acute Care Growth and Reaffirmed Outlook Support HRTX ↗
    Via Chartmill
    Heron Therapeutics Inc (NASDAQ:HRTX) Reports Q4 2025 Revenue Beat and Positive 2026 Outlook ↗
    Via Chartmill
    Which stocks are moving on Monday? ↗
    Via Chartmill
    News headline image
    Heron Therapeutics Q1 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    The market is filled with gapping stocks in Monday's session. ↗
    Via Chartmill
    News headline image
    Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance
    From Heron Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Earnings Scheduled For November 4, 2025 ↗
    Via Benzinga
    News headline image
    Heron Therapeutics to Report First Quarter 2026 Financial Results on Monday, May 11, 2026
    From Heron Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Heron (HRTX) Q4 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results
    From Heron Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Heron Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026
    From Heron Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 Growth
    From Heron Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV)
    From Heron Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Heron Therapeutics Inc (NASDAQ:HRTX) Reports Mixed Q3 2025 Results, Misses Revenue and Earnings Estimates ↗
    Via Chartmill
    News headline image
    Heron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial Progress
    From Heron Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors
    From Heron Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Heron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
    From Heron Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Friday's Intraday Session ↗
    Via Benzinga
    News headline image
    These stocks are moving in today's session ↗
    Via Chartmill
    News headline image
    Traders are paying attention to the gapping stocks in Friday's session. ↗
    Via Chartmill
    News headline image
    Heron (HRTX) Q2 Acute Care Jumps 56% ↗
    Via The Motley Fool
    Topics Economy Intellectual Property

    Frequently Asked Questions

    Is Heron Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Heron Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Heron Therapeutics, Inc. - Common Stock trade on?
    Heron Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Heron Therapeutics, Inc. - Common Stock?
    The ticker symbol for Heron Therapeutics, Inc. - Common Stock is HRTX on the Nasdaq Stock Market
    What is the current price of Heron Therapeutics, Inc. - Common Stock?
    The current price of Heron Therapeutics, Inc. - Common Stock is 0.5670
    When was Heron Therapeutics, Inc. - Common Stock last traded?
    The last trade of Heron Therapeutics, Inc. - Common Stock was at 06/02/26 10:33 AM ET
    What is the market capitalization of Heron Therapeutics, Inc. - Common Stock?
    The market capitalization of Heron Therapeutics, Inc. - Common Stock is 79.81M
    How many shares of Heron Therapeutics, Inc. - Common Stock are outstanding?
    Heron Therapeutics, Inc. - Common Stock has 80M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.